Methotrexate News and Research

RSS
Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
How anti-TNF compounds work

How anti-TNF compounds work

Combining medications often best strategy to battle rheumatoid arthritis

Combining medications often best strategy to battle rheumatoid arthritis

Mild chemo before stem cell transplant causes long-term remission of follicular lymphoma

Mild chemo before stem cell transplant causes long-term remission of follicular lymphoma

Combining medications often best strategy to battle rheumatoid arthritis

Combining medications often best strategy to battle rheumatoid arthritis

Gold-like drugs to treat arthritis

Gold-like drugs to treat arthritis

Cell growth technology promises more successful drug development

Cell growth technology promises more successful drug development

Patient choice and treatment alternatives for arthritis

Patient choice and treatment alternatives for arthritis

Inherited genes linked to toxicity of leukemia therapy

Inherited genes linked to toxicity of leukemia therapy

Results of Tocilizumab study

Results of Tocilizumab study

Bone erosion reduced by denosumab

Bone erosion reduced by denosumab

Early treatment with Infliximab and Methotrex shows benefit for rheumatoid arthritis

Early treatment with Infliximab and Methotrex shows benefit for rheumatoid arthritis

Study shows improvement of rheumatoid arthritis during pregnancy

Study shows improvement of rheumatoid arthritis during pregnancy

New era of treatment for rheumatoid arthritis

New era of treatment for rheumatoid arthritis

Most pediatric chemotherapy mistakes reach patients

Most pediatric chemotherapy mistakes reach patients

Inherited variations in certain genes linked to toxicity of leukemia therapy

Inherited variations in certain genes linked to toxicity of leukemia therapy

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Facts about rheumatoid arthritis and aging

Facts about rheumatoid arthritis and aging

Genetic risk for early death in rheumatoid arthritis

Genetic risk for early death in rheumatoid arthritis

Potential new treatment for desmoid fibromatosis

Potential new treatment for desmoid fibromatosis

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation